CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company developing chimeric engulfment receptor T-cell therapies for oncology. The company went public through a merger with Phoenix Biotech Acquisition Corp, a SPAC sponsored by Phoenix Biotech Sponsor, LLC that completed its IPO in 2021. Following the close of that combination in early 2024, CERO filed its 10-K annual report with the SEC on April 2, 2024, its first as a combined public company. CERO operates in the cell therapy segment of the biotechnology sector and trades on Nasdaq. Sign up at SpacDesk for full filings, deal history, and analytics on CERO and the broader SPAC market.